Molecular insights into the mechanism of beneficial and adverse effects of interleukin-2 (IL-
2) have resulted in the development of improved IL-2 formulations with IL-2 receptor bias …

Background: We hypothesized that in head and neck squamous cell carcinoma, the
overexpression of protumorigenic interleukin-1 (IL-1) activity within the tumor tissue is a …

We have previously described the expression of interleukin cytokines (IL)-1α, IL-1β, and IL-1
receptor antagonist (IL-1ra) in human breast cancer (HBC) tissue. Based on our previous …

In the last several decades, the number of people dying from cancer-related deaths has not
reduced significantly despite phenomenal advances in the technologies related to diagnosis …

Biopsy samples of head and neck carcinomas were investigated with regard to elafin,
secretory leukocyte protease inhibitor (SLPI), interleukin 1‐receptor antagonist [(IL) 1‐RA] …

Background: Interleukin-6 receptor antibody (IL6R) inhibits colony formation and invasion by
colorectal carcinoma (CRC) in vitro. We examined the effect of IL6R antibody on tumor …

Although the serum level of soluble interleukin-2 receptor α (sIL-2Rα) has been shown to
correlate with progression and prognosis of several cancers, data to support its clinical …

Abstract Interleukin‐1 receptor antagonist (IL‐1Ra) is an endogenous inhibitor of interleukin‐
1. The expression of IL‐1Ra and interleukin‐1α (IL‐1α) was measured in murine epidermis …

Colorectal cancer (CRC) is the third most frequent cancer worldwide and the second
greatest cause of cancer deaths. About 75% of all CRCs are sporadic cancers and arise …

Chronic inflammation has been recognized as a canonical cancer hallmark. It is
orchestrated by cytokines, which are master regulators of the tumor microenvironment (TME) …